News

Neuroscientists Gary Lewin and James Poulet at the Max Delbrück Center for Molecular Medicine have won highly coveted and competitive ERC Advanced Grants to study pain and the neural mechanisms that underlie temperature perception.

The German Research Foundation (DFG) will fund single-cell scientist Simon Haas in its Heisenberg program. Therefore, the Berlin Institute of Health at Charité (BIH) is establishing a Heisenberg professorship in systems hematology. After five years, the BIH will make the professorship permanent.

A new computer program allows scientists to design synthetic DNA segments that indicate, in real time, the state of cells. Reported by the Gargiulo lab in “Nature Communications”, it will be used to screen for anti-cancer or viral infections drugs, or to improve gene and cell-based immunotherapies.

Some hereditary genetic defects cause an exaggerated immune response that can be fatal. Using the CRISPR-Cas9 gene-editing tool, such defects can be corrected, thus normalizing the immune response, as researchers led by Klaus Rajewsky from the Max Delbrück Center now report in “Science Immunology.”

Melissa Birol of the Max Delbrück Center is looking to understand early stages of Alzheimer’s disease. Her focus is on the interplay between the lipid metabolism of nerve cells and the spread of tau protein. The Alzheimer Research Initiative is funding her work with 193,500 euros.

Cell-based immunotherapies, particularly lab-produced immune cells known as CAR T cells, show promise in treating various cancers. But how do we produce effective ones? Gaetano Gargiulo from the Max Delbrück Center will develop a novel screening tool, supported by an ERC Proof of Concept Grant.

A tumor often arises when cancer genes multiply. In this process, additional genes act as hitchhikers, potentially creating previously unknown vulnerabilities that open the door to new therapeutic approaches. This finding is reported by a team led by ECRC-scientists Anton Henssen and Jan Dörr in "Cancer Discovery."

Diseases can emerge when the body’s production of serotonin is out of whack. Researchers led by Michael Bader from the Max Delbrück Center have discovered a therapeutic agent that brings down high levels of this hormone. Their start-up, Trypto Therapeutics, aims to develop the drug for the market.

In neuromuscular diseases, neurons and muscle cells stop communicating properly. Researchers led by Mina Gouti can now model this in 2D in a culture dish. Writing about their findings in “Nature Communications”, they say the new model promises to revolutionize high-throughput drug screening studies.

For his work on aggressive glioblastomas, Dr. Gaetano Gargiulo of the Max Delbrück Center received a 10,000 euro prize from the Berlin-Brandenburg Academy of Sciences and Humanities. Donated by the Monika Kutzner Stiftung, the prize honors outstanding achievements in cancer research.